Haleon (HLN) vs Zoetis (ZTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Haleon (HLN) has outperformed Zoetis (ZTS) over the past year, gaining 2.4% versus a loss of 49.1%. Haleon is the larger company by market cap ($40.77 billion vs $30.79 billion), about 1.3 times the size. On valuation, Zoetis trades at a lower forward P/E (11.4x vs 15.0x for Haleon).
Zoetis offers the higher dividend yield (2.77% vs 0.79%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HLN | ZTS |
|---|---|---|
| Share price | $9.27 | $74.50 |
| Market cap | $40.77B | $30.79B |
| 1-day change | +0.11% | +1.94% |
| YTD return | -8.41% | -41.92% |
| 1-year return | +2.43% | -49.07% |
| 5-year return | — | -63.86% |
| P/E ratio (TTM) | 18.92 | 12.25 |
| Forward P/E | 15.00 | 11.38 |
| EPS (TTM) | $0.49 | $6.08 |
| Dividend yield | 0.79% | 2.77% |
| Annual dividend | $0.073 | $2.06 |
| Revenue (latest FY) | — | $9.47B |
| Revenue growth (YoY) | — | +2.28% |
| Net income (latest FY) | — | $2.67B |
| Gross margin | — | 71.84% |
| Net margin | — | 28.23% |
| 52-week high | $11.28 | $148.30 |
| 52-week low | $8.65 | $68.77 |
| Distance from 52-week high | -17.82% | -49.76% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +28.69% | +28.86% |
| Average volume | 13.87M | 5.46M |
| Shares outstanding | 4.40B | 413.22M |
| Employees | 24,535 | 14,500 |
| Sector | Consumer Discretionary | Health Care |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HLN has outperformed ZTS by 51.5 percentage points over the past year.
- Haleon trades at a higher earnings multiple (18.9x vs 12.3x trailing P/E).
- Zoetis offers a meaningfully higher dividend yield (2.77% vs 0.79%).
- The two companies sit in different sectors: Haleon in Consumer Discretionary and Zoetis in Health Care.
About Haleon
HLN stock →Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Consumer Discretionary · Package Goods/Cosmetics · 24,535 employees
About Zoetis
ZTS stock →Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 14,500 employees
HLN vs ZTS FAQ
Which is bigger, Haleon or Zoetis?
Haleon (HLN) is larger, with a market capitalization of $40.77B compared with $30.79B for Zoetis (ZTS).
Which stock has performed better over the past year, HLN or ZTS?
HLN returned +2.43% over the past 12 months, compared with -49.07% for ZTS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HLN or ZTS?
ZTS has the lower trailing P/E at 12.3, versus 18.9 for HLN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Haleon or Zoetis?
Zoetis has the higher yield at 2.77%, compared with 0.79% for Haleon.
Are Haleon and Zoetis in the same industry?
No. Haleon is in the Consumer Discretionary sector, while Zoetis is in Health Care.